Royalty Pharma Inks Deal for Astra’s Cliramitug (RPRX:NASDAQ)

Royalty Pharma inks deal for Astra’s cliramitug (RPRX:NASDAQ)

Royalty Pharma (RPRX) plans to spend up to $425M for a portion of royalty interest in cliramitug, a heart disease drug developed by AstraZeneca (AZN). Read more here.

Biotech deals surge to record as fear of missing out grips big pharma

The prospect of patents expiring on lucrative drugs is prompting drugmakers to hunt for the next blockbuster medicines.

Neurimmune turns future royalties into $425m pipeline cash - European Biotechnology Magazine

Swiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425 million, giving it fresh cash to invest in its remaining antibody pipeline. The post Neurimmune turns future royalties into $425m pipeline cash appeared first on European Biotechnology Magazine.